Shares of Athersys Inc. (NASDAQ:ATHX) were down 2.3% during mid-day trading on Wednesday . The stock traded as low as $2.17 and last traded at $2.17, with a volume of 218,151 shares traded. The stock had previously closed at $2.22.

Several analysts have issued reports on ATHX shares. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Monday, July 11th. Maxim Group reaffirmed a “buy” rating on shares of Athersys in a research report on Sunday, May 8th. Finally, TheStreet raised shares of Athersys from a “sell” rating to a “hold” rating in a research report on Tuesday, May 31st.

The company has a 50-day moving average price of $2.23 and a 200 day moving average price of $1.98. The company has a market cap of $183.91 million and a price-to-earnings ratio of 218.00.

Athersys (NASDAQ:ATHX) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.14. The company had revenue of $15.45 million for the quarter, compared to analysts’ expectations of $1.85 million. The firm’s revenue for the quarter was up 2016.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.16) EPS. On average, equities research analysts anticipate that Athersys Inc. will post ($0.23) EPS for the current year.

In related news, COO William Lehmann, Jr. sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $2.17, for a total transaction of $54,250.00. Following the completion of the sale, the chief operating officer now owns 279,017 shares of the company’s stock, valued at approximately $605,466.89. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.